Wassim Mchayleh, MD, MBA, FACP

Wassim Mchayleh , MD, MBA, FACP

Medical Oncologist

Cancer

Mchayleh

Overview

Wassim Mchayleh, MD, MBA, FACP, is a board-certified medical oncologist and hematologist who joined AdventHealth Medical Group from one of the largest oncology groups in the Southeast — Georgia Cancer Specialists, affiliated with Northside Hospital Cancer Institute. Prior to that, he served as Medical Director of Oncology Services and Hospice at WellStar West Georgia Medical Center. Dr. Mchayleh has held multiple academic appointments including Assistant Professor at Emory University and Program Director of Oncology Fellowship at the Lebanese American University in Beirut. He also served as clinical faculty at PCOM and the FSU School of Medicine. He was honored with the Georgia Cancer Coalition Distinguished Cancer Clinician and Scientist Award in 2011 and has contributed to multiple peer-reviewed journals in respected publications. He is fluent in English, French and Arabic.

Articles

Chimeric Antigen Receptor T-Cells: The Future Is Now

JOURNAL OF CLINICAL MEDICINE

2019

Gemtuzumab Ozogamicin as First-Line Treatment in Patients Aged 70 Years or Older With Acute Myeloid Leukemia

CANCER

2010

Adenocarcinoma of Colon Presenting As Cushing's Syndrome

JOURNAL OF CLINICAL ONCOLOGY

2010

Mitoxantrone and etoposide in patients with newly diagnosed acute myeloid leukemia with persistent leukemia after a course of therapy with cytarabine and idarubicin

LEUKEMIA & LYMPHOMA

2009

Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases

JOURNAL OF NEUROSURGERY

2008

Dendritic cell neoplasms: An overview

AMERICAN JOURNAL OF HEMATOLOGY

2007

Clue to a more serious diagnosis - Abdominal computed tomography revealed gastric pneumatosis with pneumoperitoneum and complete thrombosis of the coeliac trunk.

GUT

2005

More Publication Information

Education & Training

Education

Saint Joseph University School of Medicine, Beirut, Lebanon; Ohio State University, Columbus, OH,

Residency

Internal Medicine - George Washington University Medical Center, Washington, DC

Fellowship

University of Pittsburgh Medical Center, Pittsburgh, PA

Specialty

Medical Oncologist & Hematologist

Board Certifications

American Board of Internal Medicine

Associated Clinical Trials

NCT05629585

: D926XC00001: Phase 3, Open-Label, Randomized Study of Datopotamab Deruxtecan with or without Durvalumab Versus Investigator’s Choice of Therapy in Patients with Stage I-III Triple Negative Breast Cancer who have Residual Invasive Disease in Breast and/or Axillary Lymph Nodes Following Neoadjuvant Systemic Therapy and Surgical Resection (TROPION-Breast03)

Icon for trial | D926XC00001 : D926XC00001: Phase 3, Open-Label, Randomized Study of Datopotamab Deruxtecan with or without Durvalumab Versus Investigator’s Choice of Therapy in Patients with Stage I-III Triple Negative Breast Cancer who have Residual Invasive Disea

This study is currently enrolling.

We are doing this study to learn more about whether an investigational drug called datopotamab deruxtecan (also called Dato-DXd), either alone or in combination with another investigational drug called durvalumab, will work and ...

NCT05840211

A Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients with Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2-Negative (HER2−) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH−]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy ASCENT 07

Icon for trial | GS-US-598-6168 A Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients with Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2-Negative (HER2−) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/IS

This study is currently enrolling.

The purpose of this study is to see if sacituzumab govitecan can improve life spans of patients with HR+/HER2- metastatic breast cancer and their tumor does not grow or spread when compared to current available standard treatme ...

NCT05382299

A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan
Versus Treatment of Physician’s Choice in Patients With Previously
Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative
Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients
Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose
Tumors Do Express PD-L1

Icon for trial | GS-US-592-6238 A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do

This study is currently enrolling.

This study will be recruiting patients with previously untreated, locally advanced, inoperable or metastatic Triple-Negative Breast Cancer whose tumors do not express PD-L1 or patients previously treated with Anti PD-(L)1 Agent ...

NCT05382286

A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and
Pembrolizumab Versus Treatment of Physician’s Choice and
Pembrolizumab in Patients With Previously Untreated, Locally Advanced,
Inoperable, or Metastatic Triple-Negative Breast Cancer, Whose Tumors
Express PD-L1.

Icon for trial | GS-US-592-6173 A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced, Inoperable, or Metastatic Triple-N

This study is currently enrolling.

The purpose of this study is to see if sacituzumab govitecan in combination with pembrolizumab can improve lifespans of patients with advanced, PD-L1 positive TNBC and their tumor does not grow or spread when compared to chemot ...

NCT04457596

The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib

Icon for trial | A011801 The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucati

This study is currently enrolling.

This study is being done to answer the following question: Is the combination of T-DM1 and a newer drug tucatinib, better than usual treatment with T-DM1 alone at preventing your cancer from returning? We are doing this study b ...